Agenus Inc $2.98

down -0.01


18/9/2014 04:00 PM  |  NASDAQ : AGEN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get AGEN Trend Analysis - it has underperformed the S&P 500 by 15%

Partner Headlines

  1. Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine

    GuruFocus
  2. Morning Market Movers

    Benzinga
  3. US Stock Futures Gain Ahead Of Manufacturing PMI, Auto Sales

    Benzinga
  4. UPDATE: Agenus Announces Positive Phase 2 Results

    Benzinga
  5. Morning Market Movers

    Benzinga
  6. Benzinga's Top #PreMarket Gainers

    Benzinga
  7. UPDATE: Agenus Vaccine Shows Significant Reduction in Viral Burden after ...

    Benzinga
  8. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga
  9. Morning Market Losers

    Benzinga
  10. Glaxo Cancer Vaccine Fails, Testing Continues

    FoxBusiness
  11. Morning Market Losers

    Benzinga
  12. US Stock Futures Drop Ahead Of Jobless Claims Report

    Benzinga
  13. Agenus Therapeutics Reports GlaxoSmithKline's Magrit Study Does Not Meet ...

    Benzinga
  14. UPDATE: H.C. Wainwright & Co. Initiates Coverage on Agenus Following 4-Antibody ...

    Benzinga
  15. Agenus Announces Public Offering of Common Stock

    Benzinga
  16. Agenus Names Robert B. Stein as Chief Scientific Officer

    Benzinga
  17. Agenus to Acquire Privately Held 4-Antibody AG for $10M in Stock

    Benzinga
  18. Agenus Announces Positive Phase 2 Brain Cancer Vaccine Results Published ...

    Benzinga
  19. Agenus' HerpV Therapeutic Genital Herpes Vaccine Meets Primary Endpoint ...

    Benzinga
  20. Morning Market Movers

    Benzinga
  21. Agenus Enters into Non-Exclusive License Agreement with VaxLogic for QS-21 ...

    Benzinga
  22. Morning Market Movers

    Benzinga
  23. Agenus Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine

    Benzinga
  24. Morning Market Losers

    Benzinga
  25. GlaxoSmithKline's Phase 3 Malaria Vaccine Study Meets Primary Endpoint

    Benzinga
  26. Antigenics Inc. Reports Operating Results (10-Q)

    GuruFocus
  27. Agenus Initiates Phase 2 Study of Genital Herpes Vaccine

    Benzinga
  28. Aeras Signs Agreement with GSK to Jointly Develop TB Vaccine

    Benzinga
  29. Antigenics Inc. Reports Operating Results (10-Q)

    GuruFocus
  30. 5 Speculative Biotech Stocks to Consider Buying Now

    GuruFocus
  31. Antigenics Inc. (AGEN) CFO Shalini Sharp sells 4,564 Shares

    GuruFocus
  32. Stocks Hitting 52-Week Lows

    Benzinga
  33. A Peek Into The Market Before The Trading Starts

    Benzinga
Trading Center